Search results
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
Motley Fool via Yahoo Finance· 11 hours agoPfizer (NYSE: PFE) stock is an investing enigma. The drugmaker's shares have printed fresh 52-week lows consistently over the past two years, putting its...
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been...
Benzinga· 54 minutes agoGoldman Sachs maintains the Buy rating with a price target of $31. Bank of America Securities...
Pfizer Inc. (PFE): A New Perspective – Stocks Register
Stocks Register· 13 hours agoPfizer Inc. (NYSE:PFE) concluded the trading at $27.18 on Wednesday, May 01, with a rise of 6.09% from its closing price on previous day. Taking a look ...
Why Pfizer Stock Blasted More Than 6% Higher Today
Motley Fool via Yahoo Finance· 22 hours agoPfizer (NYSE: PFE) stock got a very effective shot in the arm on Wednesday. This was supplied by its latest earnings release, which saw the storied...
Pfizer stock gains 7% after earnings beat, company calls dividend 'secure'
Yahoo Finance via AOL· 1 day agoPfizer also faces the expiration of patents on some of its biggest drugs, including breast cancer...
What's Going With Pfizer Stock On Wednesday? - Pfizer (NYSE:PFE)
Benzinga· 1 day agoOn Wednesday, Pfizer Inc. PFE reported first-quarter adjusted EPS of $0.82, down 33% year over year,...
Albert Bourla
Time Magazine· 8 hours agoWhen Albert Bourla became CEO of Pfizer in 2019, just before the pandemic, he wanted to make Pfizer’s medicines more affordable to more patients. “No...
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings - ...
Benzinga· 2 days agoPfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has...
Pfizer earnings beat by $0.29, revenue topped estimates By Investing.com
Investing.com· 1 day agoPfizer earnings beat by $0.29, revenue topped estimates
Pfizer beats earnings estimates months after stock dipped to record lows
Crain's New York Business· 22 hours agoWhen excluding Pfizer’s Covid products, revenues increased 11%, indicating the success of its $43 billion acquisition of oncology firm Seagen and sales of blockbuster drugs ...